RD06-05 CART Cell Injection

DRUG2 trials

Sponsors

Nanjing Bioheng Biotech Co., Ltd.

Conditions

ANCA Associated VasculitisANCA Associated Vasculitis (AAV)ANCA-Associated GlomerulonephritisAnti-GBM DiseaseIIMIgA NephropathyLNMG

Early Phase 1

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

RecruitingNCT06775912

Nanjing Bioheng Biotech Co., Ltd.ANCA Associated Vasculitis (AAV), IIM, MG +4

Start: 2025-01-03End: 2027-06-01Target: 18Updated: 2026-02-02

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

RecruitingNCT07203404

Nanjing Bioheng Biotech Co., Ltd.ANCA-Associated Glomerulonephritis, ANCA Associated Vasculitis, Anti-GBM Disease +6

Start: 2025-07-24End: 2028-07-23Target: 96Updated: 2026-08-03